Arog Pharmaceuticals, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
FLT3 (including D835/ITD mutants), also PDGFR-alpha/betaSmall molecule
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2025Topline resultCrenolanibPhase 3 of crenolanib plus salvage chemotherapy (NCT03250338) in R/R FLT3-mutated AML met its primary endpoint (EFS)
Arog Pharmaceuticals, Inc. · Source ↗

Financial reports

No financial reports recorded.